Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Agex Therapeutics Inc (NY: AGE )

0.3490 UNCHANGED
Streaming Delayed Price Updated: 8:00 PM EST, Dec 6, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Agex Therapeutics Inc

AgeX Therapeutics Reports Third Quarter 2023 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AGEX THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AgeX Therapeutics, Inc. - AGE
From Kahn Swick & Foti, LLC
Via Business Wire
AGE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AgeX Therapeutics, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
Serina Therapeutics and AgeX Therapeutics Enter into Merger Agreement
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports Second Quarter 2023 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Closes $36,000,000 Debt Exchange for Preferred Stock
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Announces $36,000,000 Debt Exchange for Preferred Stock
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Announces Appeal of NYSE American Determination
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports First Quarter 2023 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Receives Stock Exchange Deficiency Letter
From AgeX Therapeutics , Inc.
Via Business Wire
AgeX Therapeutics Reports Fourth Quarter and Annual 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Receives Extension of Time to Attain Compliance With Stock Exchange Continued Listing Requirements
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports Third Quarter 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports Second Quarter 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
Dr. Joanne Hackett Appointed Chairperson of AgeX Board of Directors
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports First Quarter 2022 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports Fourth Quarter and Annual 2021 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics to Collaborate With University of California, Irvine, on Research Program for Exosome-Based Therapies for Certain Brain Disorders
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics’ Licensee ImStem Biotechnology Announces First U.S. Multiple Sclerosis Patient Dosed with IMS001
From AgeX Therapeutics, Inc.
Via Business Wire
Braeden Lichti: The Business of Anti-Aging and Rejuvenation Biotechnology
VANCOUVER, British Columbia - Dec. 31, 2021 - PRLog -- 2020-07-30: Scientists now have a better understanding into the aging process, giving us a better explanation of the cellular changes that lead... 
Via PRLog
Topics Artificial Intelligence Intellectual Property
Exposures Artificial Intelligence Intellectual Property
AgeX Therapeutics Receives Stock Exchange Deficiency Letter
From AgeX Therapeutics , Inc.
Via Business Wire
AgeX Therapeutics Reports Third Quarter 2021 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports Second Quarter 2021 Financial Results
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics and LyGenesis Terminate Merger Negotiations
From AgeX Therapeutics, Inc.
Via Business Wire
AgeX Therapeutics Reports First Quarter 2021 Financial Results and Provides Business Update
From AgeX Therapeutics
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.